Trial intelligence / Profile preview

Phase 3 randomized open-label study of glumetinib versus docetaxel in MET-overexpressing driver-negative advanced or metastatic non-small cell lung cancer after prior immunotherapy and platinum doublet chemotherapy

CTR20230451Phase 3Active

Sponsor

Haihe

Start

Jul 2023

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1